<p>在谷歌搜索和人工智能答案中查看更多來自 StockTitan 的信息。將 StockTitan 添加為首選來源 · 打開谷歌</p>
<p>在谷歌上添加</p>
<p>倫敦 --（商業資訊）--LivaNova PLC（納斯達克：LIVN），一家市場領先的醫療技術公司，宣佈在 6 月 10 日的年度股東大會後，選舉 Jette Nygaard-Andersen 為公司董事會成員。</p>
<p>“我們很高興歡迎 Jette 加入 LivaNova 的董事會，” 主席 William Kozy 説。“她帶來了深厚的醫療技術治理專業知識，經過驗證的首席執行官領導能力，以及在複雜的全球業務中進行轉型、戰略併購和數字創新的強大記錄。她在國際和上市公司董事會的經驗將為 LivaNova 增添寶貴的價值。”</p>
<p>Nygaard-Andersen 是一位擁有超過 25 年領導經驗的資深高管和董事會主席，曾在高度監管的國際企業中任職。她目前是丹麥全球醫療器械公司 Coloplast A/S 的董事會主席。自 2015 年以來，她一直擔任 Coloplast 的非執行董事，包括擔任其薪酬與提名委員會的主席以及審計委員會的成員。</p>
<p>Nygaard-Andersen 在多家全球組織中擔任過高級領導職務，擁有跨多個行業和地區的治理、戰略和運營執行背景。作為全球體育博彩和遊戲公司 Entain plc 的首席執行官和執行董事，她領導了一項全面的業務轉型並實現了顯著增長。在加入 Entain 之前，Nygaard-Andersen 在納斯達克北歐上市的歐洲媒體、娛樂和遊戲集團 Modern Times Group AB 工作了 16 年，期間歷任多個高級執行職位，包括首席運營官和多個業務單元的首席執行官。她擁有哥本哈根大學的工商管理碩士學位，專注於金融。</p>
<p>“LivaNova 擁有堅實的基礎和明確的戰略前進方向，” Nygaard-Andersen 説。“我期待與董事會和管理團隊合作，支持公司在推進創新醫療技術方面的持續增長和影響，這些技術改善了全球患者的生活。”</p>
<p>與 Nygaard-Andersen 的任命同時，Sharon O’Kane 博士在決定不尋求連任後辭去了董事會職務。O’Kane 於 2015 年在 LivaNova 成立後被任命為董事，最近慶祝了她作為董事會成員的十週年。</p>
<p>“我們對 Sharon 在超過十年的傑出和奉獻服務中對公司的重要貢獻深表感謝，” Kozy 説。“Sharon 在任期內對 LivaNova 產生了持久的影響。她的領導力、洞察力和承諾，特別是在 2017 年擔任我們提名與公司治理委員會主席以及 2023-2024 年擔任首席獨立董事期間，發揮了重要作用，引導公司度過許多關鍵里程碑。”</p>
<p>Brooke Story 於 2022 年被任命為董事，將接替 O’Kane 擔任提名與公司治理委員會的主席，她將與 Nygaard-Andersen、Chris Barry 和 Stacy Enxing Seng 一起工作。Enxing Seng 將結束她作為薪酬與人力資本管理（CHCM）委員會主席的任期，Peter Wilver 將接任該職位，並與 Enxing Seng、Susan Podlogar 和 Francesco Bianchi 一起工作。Todd Schermerhorn 將繼續擔任審計與合規委員會的主席，Barry、Wilver 和 Don Zurbay 將作為成員。Kozy 將繼續擔任董事會主席。</p>
<p><strong>關於 LivaNova</strong></p>
<p>LivaNova PLC 是一家全球醫療技術公司，擁有近五十年的經驗和改變人們生活軌跡的願景。通過在特定神經和心臟疾病領域的巧妙醫療解決方案，LivaNova 努力點燃患者的轉機。公司總部位於倫敦，擁有約 3300 名員工，並在 100 多個國家開展業務，服務於全球患者、醫療專業人員和醫療系統。有關更多信息，請訪問 www.livanova.com。</p>
<p><strong>安全港聲明</strong></p>
<p>本新聞稿包含關於公司目標、信念、期望、戰略、目標、計劃、基本假設和其他不一定基於歷史事實的 “前瞻性聲明”。這些聲明包括但不限於關於董事會的聲明。實際事件可能因各種因素而與我們的前瞻性聲明中所指示的情況有重大不同，包括公司最近的 10-K 表格年報第 1A 項中列出的因素，以及季度報告 10-Q 表格和當前報告 8-K 表格中包含的任何風險因素。LivaNova 沒有義務更新本新聞稿中包含的信息，以反映隨後發生的事件或情況。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MTE3OTY2NzByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MTE3OTY2NzByMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260611796670/en/</p>
<p><strong>LivaNova 投資者關係和媒體聯繫人</strong></p>
<p>+1 281-895-2382</p>
<p><strong>Briana Gotlin</strong></p>
<p>投資者關係副總裁</p>
<p>InvestorRelations@livanova.com</p>
<p><strong>Deanna Wilke</strong></p>
<p>企業傳播副總裁</p>
<p>Corporate.Communications@livanova.com</p>
<p>來源：LivaNova PLC</p>

LIVN

<p>LivaNova PLC 宣佈在 6 月 10 日的年度股東大會後選舉 Jette Nygaard-Andersen 加入其董事會。Nygaard-Andersen 擁有豐富的醫療科技治理和首席執行官領導經驗。同時，Sharon O’Kane 博士在服務十年後辭職。公告還詳細説明了董事會委員會主席的變更，包括 Brooke Story 接替 O’Kane 擔任提名與公司治理委員會主席</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在谷歌搜索和人工智能答案中查看更多來自 StockTitan 的信息。將 StockTitan 添加為首選來源 · 打開谷歌</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在谷歌上添加</p>
</div><p>LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company’s Board of Directors after its Annual General Meeting of shareholders on June 10.</p>
<div class="lb-trans"><p>倫敦 --（商業資訊）--LivaNova PLC（納斯達克：LIVN），一家市場領先的醫療技術公司，宣佈在 6 月 10 日的年度股東大會後，選舉 Jette Nygaard-Andersen 為公司董事會成員。</p>
</div><p>“We’re pleased to welcome Jette to LivaNova’s Board,” said William Kozy, Chair. “She brings deep medtech governance expertise, proven CEO leadership, and a strong track record of transformation, strategic M&amp;A, and digital innovation across complex global businesses. Her international and public company board experience will be a valuable addition to LivaNova.”</p>
<div class="lb-trans"><p>“我們很高興歡迎 Jette 加入 LivaNova 的董事會，” 主席 William Kozy 説。“她帶來了深厚的醫療技術治理專業知識，經過驗證的首席執行官領導能力，以及在複雜的全球業務中進行轉型、戰略併購和數字創新的強大記錄。她在國際和上市公司董事會的經驗將為 LivaNova 增添寶貴的價值。”</p>
</div><p>Nygaard-Andersen is a tenured executive and board chair with more than 25 years of leadership experience in highly regulated international businesses. She is currently Chair of the Board for Coloplast A/S, a global medical device company based in Denmark. She has served as a Non-Executive Director of Coloplast since 2015, including as Chair of its Remuneration and Nomination Committee and as a member of its Audit Committee.</p>
<div class="lb-trans"><p>Nygaard-Andersen 是一位擁有超過 25 年領導經驗的資深高管和董事會主席，曾在高度監管的國際企業中任職。她目前是丹麥全球醫療器械公司 Coloplast A/S 的董事會主席。自 2015 年以來，她一直擔任 Coloplast 的非執行董事，包括擔任其薪酬與提名委員會的主席以及審計委員會的成員。</p>
</div><p>Nygaard-Andersen has held senior leadership roles within multiple global organizations, with a background spanning governance, strategy, and operational execution across a range of industries and geographies. As Chief Executive Officer and Executive Director of Entain plc, a global sports betting and gaming company, she led a comprehensive business transformation and delivered significant growth. Prior to Entain, Nygaard-Andersen spent 16 years at Modern Times Group AB, a Nasdaq Nordic-listed European media, entertainment, and gaming group, where she progressed through a series of senior executive positions including as Chief Operating Officer and, later, as CEO of multiple business units. She holds a Master of Science degree in Business Administration, with a concentration in Finance, from the University of Copenhagen.</p>
<div class="lb-trans"><p>Nygaard-Andersen 在多家全球組織中擔任過高級領導職務，擁有跨多個行業和地區的治理、戰略和運營執行背景。作為全球體育博彩和遊戲公司 Entain plc 的首席執行官和執行董事，她領導了一項全面的業務轉型並實現了顯著增長。在加入 Entain 之前，Nygaard-Andersen 在納斯達克北歐上市的歐洲媒體、娛樂和遊戲集團 Modern Times Group AB 工作了 16 年，期間歷任多個高級執行職位，包括首席運營官和多個業務單元的首席執行官。她擁有哥本哈根大學的工商管理碩士學位，專注於金融。</p>
</div><p>“LivaNova has a strong foundation and a clear strategic path forward,” Nygaard-Andersen said. “I look forward to working with the Board and management team to support the Company’s continued growth and impact as it advances innovative medical technologies that improve the lives of patients worldwide.”</p>
<div class="lb-trans"><p>“LivaNova 擁有堅實的基礎和明確的戰略前進方向，” Nygaard-Andersen 説。“我期待與董事會和管理團隊合作，支持公司在推進創新醫療技術方面的持續增長和影響，這些技術改善了全球患者的生活。”</p>
</div><p>Concurrent with Nygaard-Andersen’s appointment, Dr. Sharon O’Kane stepped down from the Board after deciding not to seek re-election. O’Kane, who was appointed to her position in 2015 following the formation of LivaNova, recently celebrated her 10th anniversary as a Board member.</p>
<div class="lb-trans"><p>與 Nygaard-Andersen 的任命同時，Sharon O’Kane 博士在決定不尋求連任後辭去了董事會職務。O’Kane 於 2015 年在 LivaNova 成立後被任命為董事，最近慶祝了她作為董事會成員的十週年。</p>
</div><p>“We are deeply grateful to Sharon for her many important contributions to the Company during more than a decade of distinguished and dedicated service,” Kozy said. “Sharon has made a lasting impact on LivaNova during her tenure. Her leadership, insight, and commitment, particularly in her role as Chair of our Nominating and Corporate Governance Committee since 2017 and time as Lead Independent Director between 2023-2024, have played an important role in guiding the Company through many key milestones.”</p>
<div class="lb-trans"><p>“我們對 Sharon 在超過十年的傑出和奉獻服務中對公司的重要貢獻深表感謝，” Kozy 説。“Sharon 在任期內對 LivaNova 產生了持久的影響。她的領導力、洞察力和承諾，特別是在 2017 年擔任我們提名與公司治理委員會主席以及 2023-2024 年擔任首席獨立董事期間，發揮了重要作用，引導公司度過許多關鍵里程碑。”</p>
</div><p>Brooke Story, who was appointed to the Board in 2022, will succeed O’Kane as Chair of the Nominating and Corporate Governance Committee, where she will serve alongside Nygaard-Andersen, Chris Barry, and Stacy Enxing Seng. Enxing Seng will conclude her tenure as Chair of the Compensation and Human Capital Management (CHCM) Committee, and Peter Wilver will assume that position, where he will be joined by Enxing Seng, Susan Podlogar, and Francesco Bianchi. Todd Schermerhorn will remain Chair of the Audit and Compliance Committee, with Barry, Wilver, and Don Zurbay as members. Kozy will continue to serve as Chair of the Board.</p>
<div class="lb-trans"><p>Brooke Story 於 2022 年被任命為董事，將接替 O’Kane 擔任提名與公司治理委員會的主席，她將與 Nygaard-Andersen、Chris Barry 和 Stacy Enxing Seng 一起工作。Enxing Seng 將結束她作為薪酬與人力資本管理（CHCM）委員會主席的任期，Peter Wilver 將接任該職位，並與 Enxing Seng、Susan Podlogar 和 Francesco Bianchi 一起工作。Todd Schermerhorn 將繼續擔任審計與合規委員會的主席，Barry、Wilver 和 Don Zurbay 將作為成員。Kozy 將繼續擔任董事會主席。</p>
</div><p><strong>About LivaNova</strong></p>
<div class="lb-trans"><p><strong>關於 LivaNova</strong></p>
</div><p>LivaNova PLC is a global medical technology company built on nearly five decades of experience and a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. Headquartered in London, with approximately 3,300 employees and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.</p>
<div class="lb-trans"><p>LivaNova PLC 是一家全球醫療技術公司，擁有近五十年的經驗和改變人們生活軌跡的願景。通過在特定神經和心臟疾病領域的巧妙醫療解決方案，LivaNova 努力點燃患者的轉機。公司總部位於倫敦，擁有約 3300 名員工，並在 100 多個國家開展業務，服務於全球患者、醫療專業人員和醫療系統。有關更多信息，請訪問 www.livanova.com。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港聲明</strong></p>
</div><p>This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the Board of Directors. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.</p>
<div class="lb-trans"><p>本新聞稿包含關於公司目標、信念、期望、戰略、目標、計劃、基本假設和其他不一定基於歷史事實的 “前瞻性聲明”。這些聲明包括但不限於關於董事會的聲明。實際事件可能因各種因素而與我們的前瞻性聲明中所指示的情況有重大不同，包括公司最近的 10-K 表格年報第 1A 項中列出的因素，以及季度報告 10-Q 表格和當前報告 8-K 表格中包含的任何風險因素。LivaNova 沒有義務更新本新聞稿中包含的信息，以反映隨後發生的事件或情況。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MTE3OTY2NzByMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260611796670r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260611796670/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260611796670/en/</p>
</div><p><strong>LivaNova Investor Relations and Media Contacts</strong></p>
<div class="lb-trans"><p><strong>LivaNova 投資者關係和媒體聯繫人</strong></p>
</div><p>+1 281-895-2382</p>
<div class="lb-trans"><p>+1 281-895-2382</p>
</div><p><strong>Briana Gotlin</strong></p>
<div class="lb-trans"><p><strong>Briana Gotlin</strong></p>
</div><p>VP, Investor Relations</p>
<div class="lb-trans"><p>投資者關係副總裁</p>
</div><p>InvestorRelations@livanova.com</p>
<div class="lb-trans"><p>InvestorRelations@livanova.com</p>
</div><p><strong>Deanna Wilke</strong></p>
<div class="lb-trans"><p><strong>Deanna Wilke</strong></p>
</div><p>VP, Corporate Communications</p>
<div class="lb-trans"><p>企業傳播副總裁</p>
</div><p>Corporate.Communications@livanova.com</p>
<div class="lb-trans"><p>Corporate.Communications@livanova.com</p>
</div><p>Source: LivaNova PLC</p>
<div class="lb-trans"><p>來源：LivaNova PLC</p>
</div>

Jette Nygaard-Andersen Joins LivaNova Board as a New Director | LIVN Stock News

Jette Nygaard-Andersen 加入 Livanova 董事會，擔任新董事 | LIVN 股票新聞